

Press Release  
October 8, 2009  
Gothenburg

## Vitrolife signs collaboration agreement with Cellartis

**Vitrolife has entered into a new 3-year collaboration agreement with Cellartis AB regarding the development of new products for the culture, handling and differentiation of stem cells. The agreement extends the previous collaboration between the companies.**

"The stem cell field is experiencing strong growth, not least since President Obama lifted the ban on research into certain stem cell lines," says Tony Winslöf, Head of Business Development at Vitrolife. The collaboration with Cellartis comes at the right time to develop the stem cell products of tomorrow, meeting the scientific, regulatory and commercial demands of the future.

"Cellartis is a world-leading company with regard to competence above all in the field of pluripotent stem cells, and as such is a valuable resource in developing the right products for a rapidly growing market," says Magnus Nilsson, Vitrolife's CEO, who also points out that "stem cell culture is difficult and both Vitrolife and Cellartis have long experience of optimizing culture environments for sensitive cells."

The financial scope of the agreement will not be made public.

Gothenburg  
October 8, 2009

Magnus Nilsson  
CEO

**Queries should be addressed to:**

Magnus Nilsson, CEO, phone +46 31 721 80 61.  
Eva Nilsagård, CFO, phone +46 31 721 80 13.

Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body in order to select usable organs and keeping them in optimal condition while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife today has approximately 160 employees and its products are sold in more than 85 markets. The company is headquartered in Gothenburg, Sweden, and there are subsidiaries in USA, Australia, France and Italy. Production facilities are located in Sweden and the USA. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.  
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: [info@vitrolife.com](mailto:info@vitrolife.com). Homepage: [www.vitrolife.com](http://www.vitrolife.com).

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.